Weight loss in breast cancer patient management

Journal of Clinical Oncology

Volumn 20, Issue 4, 2002, Pages 1128-1143

  Chlebowski, Rowan T ^a   Aiello, Erin ^a   McTiernan, Anne ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; LIFESTYLE; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT PLANNING; TUMOR GROWTH; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; EXERCISE; FEMALE; HUMANS; INTERVENTION STUDIES; LIFE STYLE; MIDDLE AGED; OBESITY; PROGNOSIS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0037083568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.4.1128     Document Type: Article

References (158)

1. The association of body weight gain and recurrence of cancer of the breast
2. The prognostic implications of obesity for the surgical cure of breast cancer
3. Body weight and prognosis in breast cancer
4. Cholesterol and obesity as prognostic factors in breast cancer
5. Body size and survival in premenopausal breast cancer
6. A study of the effect of weight and dietary fat on breast cancer survival time
7. Body size, reproductive factors, and breast cancer survival
8. Risk factors and 10-year breast cancer survival in northern Alberta
9. Race, nutritional status, and survival from breast cancer
10. Obesity as prognostic factors in breast cancer
11. Survival of breast cancer patients and body size indicators
12. The effect of pre-morbid height and weight on the survival of breast cancer patients
13. Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking: A population-based study
14. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer
15. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival
16. Serum beta-lipoprotein, serum cholesterol and Quetelet's index as predictors for survival of breast cancer patients
17. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer
18. Oral contraceptives and prognosis in breast cancer: Effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer
19. Pre-morbid body size and the prognosis of women with breast cancer
20. Pre-morbid body-mass-index in breast cancer: Reversed effect on survival in hormone receptor negative patients
21. Social class and weight as prognostic factors in early breast cancer
22. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients
23. The effect of dietary exposures on recurrence and mortality in early stage breast cancer
24. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study
25. Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during lifespan, and survival from breast carcinoma
26. Adjuvant tamoxifen may be relatively ineffective in women with diabetes and breast cancer
27. Body weight and prognosis in breast cancer
28. The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advance cancer of the breast
29. Body size and menopausal status in relation to the pattern of spread in recurrent breast cancer
30. An examination of obesity and breast cancer survival in post-menopausal women
31. Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project
32. The influence of obesity on the disease-free survival in primary breast cancer
33. Survival of women with node negative breast cancer in the Auckland region
34. Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States
35. Development of a weight management program in women with newly diagnosed locoregional breast cancer
36. Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis
37. Breast cancer and weight gain: An unexpected finding
38. Weight gain during adjuvant therapy for stage II breast cancer
39. Weight gain during adjuvant chemotherapy or hormono-chemotherapy for stage II breast cancer evaluated in relation to disease free survival (DFS)
40. Weight gain among stage II breast cancer patient: A study of five factors
41. Dietary fat consumption and survival among women with breast cancer
42. Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast
43. Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy
44. Weight gain in women with localized breast cancer: A descriptive study
45. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer
46. Weight gain with breast cancer adjuvant treatment
47. Adherence to a dietary fat intake reduction program in postmenopausal women with resected breast cancer
48. Why women gain weight with adjuvant chemotherapy for breast cancer
49. Weight gain in women receiving adjuvant chemotherapy for breast cancer
50. Computerized tomography assessment of women with weight changes associated with adjuvant treatment for breast cancer
51. Weight gain in women diagnosed with breast cancer
52. Multidisciplinary weight management in locoregional breast cancer: Results of a phase II study
53. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis
54. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy
55. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy
56. Eating pathology and obesity in women at risk for breast cancer recurrence
57. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
58. Changes in body composition during breast cancer chemotherapy with the CMF-regimen
59. Weight gain during adjuvant therapy in high risk pre/perimenopausal breast cancer patients: Analysis of a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) phase III study
60. Weight change in women treated with adjuvant therapy or observed following mastectomy for node positive breast cancer
61. Weight gain in early-stage breast cancer: Where do we go from here?
62. Direct observations of surgical wound infections at a comprehensive cancer center
63. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer
64. Tamoxifen therapy for breast cancer and endometrial cancer risk
65. Severe obesity as a risk factor for congestive heart failure (CHF) in women receiving doxorubicin (A) for breast cancer (BC)
66. Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base
67. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older
68. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors
69. Qualify of life assessment in the adjuvant setting, is it relevant?
70. The persistent impact of breast carcinoma on functional health status: Prospective evidence from the Nurses' Health Study
71. Weight gain in women with breast cancer receiving adjuvant chemotherapy
72. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer
73. A prospective study of weight change and health-related quality of life in women
74. Descriptive anthropometric reference data for older Americans
75. Prevalence of leisure-time and occupational physical activity among employed adults: United States, 1990
76. Prevalence and correlates of recreational physical activity in women aged 50-64 years
77. Epidemiology of breast cancer
78. Estrogen and the risk of breast cancer
79. Hormone and bone mineral status in endurance-trained and sedentary postmenopausal women
80. The epidemiology of serum sex hormones in postmenopausal women
81. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women
82. Association of dietary and lifestyle factors with sex hormones in postmenopausal women
83. Role of the insulin-like growth factor family in cancer development and progression
84. Hyperinsulinemia and sex hormones in healthy premenopausal women: Relative contribution of obesity, obesity type, and duration of obesity
85. Anthropometric, computed tomography and fat cell data in an obese population: Relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones
86. Circulating levels of sex hormones and their relation to risk factors for breast cancer: A cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom)
87. Divergent effects of short-term, very-low-calorie diet on insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum concentrations in premenopausal women with obesity
88. Sex hormone levels in serum in relation to the development of breast cancer
89. Sex hormone levels in serum in relation to the development of breast cancer
90. A prospective study of endogenous hormones and breast cancer
91. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
92. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk
93. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women
94. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
95. Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in MORE Trial participants
96. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
97. Serum and urinary androgens and risk of breast cancer in postmenopausal women
98. Serum sex hormone levels after menopause and subsequent breast cancer
99. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5 androstene-3β, 17β-diol to risk of breast cancer in postmenopausal women
100. Body mass and sex hormones in postmenopausal breast cancer patients
101. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
102. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
103. Perimenopausal weight gain and progression of breast cancer precursors
104. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women
105. Regulation of estrogen biosynthesis by human adipose cells
106. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired cohort study
107. Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant therapy with tamoxifen
108. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Intervention in Oncologia (GIVIO)
109. Reproductive and hormonal alterations in obesity
110. Body mass as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or megestrol acetate
111. Dietary fat reduction and plasma estradiol concentration in post-menopausal women
112. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients
113. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer
114. The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients
115. Reducing bioavailable sex hormones through a comprehensive change in diet: The diet and androgens (DIANA) randomized trial
116. Dietary fat intake and endogenous sex steroid hormone levels in postmenopausal women
117. Effects of exercise on the serum concentrations of FSH, LH, progesterone, and estradiol
118. Induction of menstrual disorders by strenuous exercise in untrained women
119. Prospective decrease in progesterone concentrations in female lightweight rowers during the competition season compared with the off season: A controlled study examining weight loss and intensive exercise
120. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
121. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
122. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X
123. The effect of weight loss on sex steroid secretion and binding in massively obese women
124. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: Effect of shortand long-term weight reduction
125. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults the evidence report
126. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
127. Maintenance of treatment effects in the long-term management of obesity
128. The impact of the Black American Lifestyle Intervention on weight loss, blood pressure, glycemic and lipid profile
129. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat: The Iowa Women's Health Study
130. Diet and risk for breast cancer recurrence and survival
131. Dietary factors and the survival of women with breast carcinoma
132. Dietary change as a strategy for preventing cancer
133. Primary care: Reducing the risk of breast cancer
134. Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence
135. Long term adherence to dietary fat reduction in the Women's Intervention Nutrition Study (WINS)
136. Reduction in fat intake is not associated with weight loss in most women after breast cancer diagnosis
137. Change in women's diet and body mass following intensive intervention for early-stage breast cancer
138. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: Results from a randomized trial-Canadian Diet and Breast Cancer Prevention Study Group
139. Design of the Women's Health Initiative clinical trial and observational study: The Women's Health Initiative Study Group
140. Macronutrient intake and change in mammographic density at menopause: A randomized trial
141. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of a randomized controlled trial
142. Sleep disturbance, fatigue, and exercise in women receiving radiation therapy or chemotherapy for breast cancer
143. The effect of aerobic exercise on patient reports of nausea
144. Effects of aerobic interval training on cancer patients' functional capacity
145. Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy
146. A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy
147. The effect of physical activity on the emotional and physical recovery of women with a history of breast cancer
148. Home-based exercise for breast cancer survivors: The moving forward study
149. Randomized trial of dietician counseling to try to prevent weight gain associated with breast cancer adjuvant chemotherapy
150. Weight loss in obese breast cancer survivors: Novel strategies
151. A feasibility study on weight reduction in obese postmenopausal breast cancer patients
152. A pill for all by the year 2000?
153. Tamoxifen as adjuvant breast cancer therapy
154. Tamoxifen for early breast cancer: A review of the randomized trials
155. Conflicting results from tamoxifen studies: A simple explanation
156. Aromatase inhibitors in the treatment and prevention of breast cancer